Enlightening light chain deposition disease

Slides:

Advertisements

Similar presentations

MGUS (interpreting the test you didnt order) Family Medicine Review Course 2011 Christian Cable, MD, FACP.

Advertisements

Diabetic Nephropathy.  Over 40% of new cases of end-stage renal disease (ESRD) are attributed to diabetes.  In 2001, 41,312 people with diabetes began.

Serum Protein Electrophoresis

Long-Term Biological Variation of Serum Protein Electrophoresis M-Spike, Urine M-Spike, and Monoclonal Serum Free Light Chain Quantification: Implications.

Renal Clearance The renal clearance of a substance is the volume of plasma that is completely cleared of the substance by the kidneys per unit time.

Protein casts, nodular glomerulosclerosis in a graft biopsy samples Agnieszka Perkowska-Ptasinska Transplantation Institute, Medical University of Warsaw,

Plasma cell disorders Dr. hassanali vahedian ardakani Medical oncologist hematologist 2013.

1.Defining Plasma cell disorders/Multiple Myeloma 2.Identification of different plasma cell disorders. 3.Diagnosis and workup for plasma cell disorders/Multiple.

Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney Sophina Hissaund FY2.

High Cut-Off Hemodialyzers Efficiently Remove Immunoglobulin Free Light Chains And Reduce Tubular Injury Induced By Plasma Of Patients With Multiple Myeloma.

2-4. Estimated Renal Function Estimated GFR = 1.8 x (Cs) x (age) Cockcroft-Gault eq. – Estimated creatine clearance (mL/min) = (140 – age x body weight,

Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome by Annamaria Brioli, Hannah Giles,

Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.

Myeloma and the Kidney Ryan Sanford How Often is the Kidney Involved Symptomatic MM: CRAB – hyperCalcemia – Renal dysfunction – Anemia – Bone.

Trial profile Mann JF et al. Lancet 2008;372:

Biochemical and genetic evaluation in amyloidosis

A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with.

R4 Jae Joon Han.

M protein detection and characterization

From: Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney DiseaseA Secondary Analysis.

The EuLITE (Ongoing) Source

The EuLITE (Ongoing).

Globular Protein Made of amino acid chains

Association Between Cardiac Biomarkers and the Development of ESRD in Patients With Type 2 Diabetes Mellitus, Anemia, and CKD Akshay S. Desai, MD, MPH,

Volume 67, Pages S1-S7 (June 2005)

Renal Function Testing

MBL: mostly benign lymphocytes, but…

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

by Nataliya Melnyk, and Jonathan Harrison

Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma by Shaji K. Kumar, Betsy LaPlant,

Monoclonal Gammopathy of Undetermined Significance

Figure 1.17 of the 2016 US Renal Data System Annual Data Report, Volume 2, chapter 1 showing the trends in the number of patients with incident ESRD (in.

A cell by any other name by Narla Mohandas Blood

A young patient with multiple myeloma

Clinical Challenges in the Transplant-Eligible Patient With Newly Diagnosed Multiple Myeloma.

The role of complete response in multiple myeloma

Management of hypertension in patients with chronic kidney disease

Monoclonal Gammopathy–Associated Proliferative Glomerulonephritis

Jesse C. Seegmiller, John H. Eckfeldt, John C. Lieske

by Nelson Leung, Samih H. Nasr, and Sanjeev Sethi

Stage C or not stage C…? by Claire Dearden Blood

Therapeutic advances demand accurate typing of amyloid deposits

Renal Manifestations of Plasma Cell Disorders

Recurrent AA Amyloidosis in a Kidney Transplant

Christophe Sirac, Frank Bridoux Kidney International

Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma by Angela Dispenzieri,

Corrections to "Estimating the glomerular filtration rate from serum creatinine is better than from cystatin C for evaluating risk factors associated.

Advances in CKD Detection and Determination of Prognosis: Executive Summary of the National Kidney Foundation–Kidney Early Evaluation Program (KEEP) 2012.

Gastric maltoma with M proteins in serum and gastric juice

Your Kidneys May Outlive You

GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration

Meeting the challenges of the new K/DOQI guidelines

Erratum American Journal of Kidney Diseases

Volume 73, Issue 11, Pages (June 2008)

High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin.

An integrated biochemical prediction model of all-cause mortality in patients undergoing lower extremity bypass surgery for advanced peripheral artery.

Alect2 amyloidosis: primum non nocere (first, do no harm)

Statins and other agents for vascular inflammation

American Journal of Kidney Diseases

U-shaped effect of eGFR and mortality

Volume 76, Issue 3, Pages (August 2009)

Methods for guideline development

Volume 85, Issue 5, Pages (May 2014)

by Giovanni Palladini, and Giampaolo Merlini

Volume 80, Issue 10, Pages (November 2011)

Figure 3 Models of monoclonal immunoglobulin-induced glomerulopathies

Clinical Challenges in the Transplant-Eligible Patient With Newly Diagnosed Multiple Myeloma.

by Robert A. Kyle, and S. Vincent Rajkumar

Among three residual kidney function (RKF) indices, only residual urine volume (UV) indicated an independent prognostic value in patients with UV≥0.1 or.

by Chatree Chai-Adisaksopha, Davide Matino, and Alfonso Iorio

Presentation transcript:

Enlightening light chain deposition disease by Giampaolo Merlini, and Giovanni Palladini Blood Volume 126(26):2770-2771 December 24, 2015 ©2015 by American Society of Hematology

Impact of response on progression of renal damage and challenging electrophoretic pattern in light chain deposition disease. Impact of response on progression of renal damage and challenging electrophoretic pattern in light chain deposition disease. (A) Mean annual change in estimated glomerular filtration rate (eGFR) in patients attaining a VGPR or CR, compared with patients reaching less than VGPR. Only 14% of patients in VGPR or CR required dialysis, compared with 64% of other subjects. (B) The serum electrophoresis scan (top) and anti-κ immunofixation (bottom) show no monoclonal immunoglobulin in a patient with LCDD and with a serum κ free LC (FLC) concentration of 609 mg/L and a greatly abnormal FLC ratio. In our population of 68 patients with LCDD, a monoclonal protein was detected by serum and urine electrophoresis/immunofixation in only 60% of the patients, whereas FLC concentration and ratio were abnormal in all. S, serum; U, urine. Giampaolo Merlini, and Giovanni Palladini Blood 2015;126:2770-2771 ©2015 by American Society of Hematology